Illumina, Inc. vs Oracle Corporation — how do they compare? Illumina, Inc. trades at $265 (market cap $39.95B), while Oracle Corporation trades at $137.55 (market cap $411.34B). The key difference: Oracle Corporation is far larger — about 10.3× Illumina, Inc.'s market cap, and Oracle Corporation pays a 1.47% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Oracle Corporation for 72 Days on average.
| ILMN | ORCL | |
|---|---|---|
Market Cap | $39.95B | $411.34B |
Volume | 3,169,503 | 41,276,815 |
Sector | Health | Technology |
52-Week High | $293.69 | $313.00 |
52-Week Low | $91.00 | $114.99 |
Typical Hold Time | 83 Days | 72 Days |
Enterprise Value | $41.31B | $535.15B |
Dividend Yield | — | 1.47% |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
Oracle (ORCL) is trading at $135.56, down 6.36% over the past 24 hours amid broader market concerns about AI spending cycles and higher borrowing costs. The stock shows strong fundamental performance with three consecutive quarterly earnings beats and robust revenue growth of 21.67% net income margin for 2025. Technical indicators signal bearish momentum with the price below key resistance levels, while analyst sentiment remains overwhelmingly positive with a $236.52 consensus price target representing significant upside potential.
Oracle presents a compelling investment opportunity with strong AI cloud demand driving 120% infrastructure growth, though near-term headwinds include market volatility and aggressive capital expenditure. The company's improving debt-to-asset ratio and consistent earnings growth support long-term value, but investors should monitor execution risks in the competitive cloud infrastructure space and potential macroeconomic pressures on tech valuations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →